Rating Change
Citigroup analysts reiterated a Buy rating on Telix Pharmaceuticals Limited (NASDAQ:TLX) on July 07, 2026.
reiterateNASDAQ:TLX
Citigroup Reiterates Buy Rating on Telix Pharmaceuticals Limited (TLX)
Rating Change Citigroup analysts reiterated a Buy rating on Telix Pharmaceuticals Limited (NASDAQ:TLX) on July 07, 2026. Market Context Telix Pharmaceuticals Limited operates in…
Market Context
Telix Pharmaceuticals Limited operates in the Healthcare sector. The stock currently trades at $11.74 with a market capitalization of $3.2B.
Analyst coverage from Citigroup provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Telix Pharmaceuticals Limited.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Telix Pharmaceuticals Limited
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 07, 2026 | Citigroup | Buy | N/A |
| Jul 07, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 06, 2026 | Wedbush | Outperform | N/A |
| Apr 13, 2026 | Wedbush | Outperform | N/A |
| Apr 13, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View TLX Stock Page
Frequently Asked Questions
What does a Buy rating mean for TLX?
A Buy rating from Citigroup reflects the analyst's outlook on Telix Pharmaceuticals Limited (NASDAQ:TLX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TLX forecast page.